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ighty percent of human colon can-
cers carry a mutation in adenoma-
tous polyposis coli (APC) protein. 
APC is an adaptor protein that helps regu-
late the cytoskeleton and also modulates the 
behavior of signaling proteins like -catenin. 
Inke Näthke is working to understand 
APC’s normal functions in cells, and why 
APC mutations are so frequently associated 
with cancers of the gut (1–5).
As a graduate student studying the 
structure and function of clathrin in 
Frances Brodsky’s lab at UCSF (6), 
Näthke was focused on biochemistry and 
her lab mates teased her for working exclu-
sively with purifi  ed proteins. But as a 
postdoc in James Nelson’s lab at Stan-
ford, Näthke made the discovery that 
would shape her career through the lens 
of a microscope: a striking and unusual 
interaction between APC and the micro-
tubule cytoskeleton (7).
Her interest piqued by that initial 
observation, Näthke has uncovered new 
secrets about APC ever since. We called 
her at her laboratory at the University of 
Dundee in Scotland to dis-
cuss how APC affects cell 
biology, tissue architecture, 
and her career.
CHOICE
Where did you grow up?
In Germany. I stayed there 
until the end of high school. 
I had the blessing—or maybe 
it was a curse—of being 
pretty good at many differ-
ent things. I was good at 
languages. I enjoyed math, 
chemistry, and music. As a 
result, I didn’t really know what I wanted 
to do for a career. If I’d gone to college 
immediately after high school, I’d have had 
to choose a particular subject to study, but 
I didn’t feel ready to make that choice. 
Fortunately, my parents were understanding, 
and when I said I wanted to take some time 
off before college, they supported me.
I wanted to go to a foreign country, to 
experience a different way of life, and 
the easiest way to do that was to become 
an au pair. So I wrote to newspapers in 
Ireland, and I looked for jobs in New 
Zealand. I wasn’t really looking to go to 
the United States, but a friend of my father’s 
helped me fi  nd a place with a family in 
San Jose, California. The family was 
wonderful. They welcomed me into their 
home and I fell in love with California. 
I was supposed to go home after a year 
but when the time came, I didn’t want to 
leave. By that time, too, I had discovered 
the college system in the States, which 
compared to the one in Germany was 
very open-ended; you didn’t have to declare 
a major right away. I thought that sounded 
perfect for me.
So you went to college in the States?
It turned out I had to go back to Germany 
for a year to get some academic prerequi-
sites out of the way, but I fi  nally enrolled 
at San Jose State University as a premed 
student. I quickly decided that wasn’t for 
me, partially because I had 
discovered biochemistry 
and decided that was fas-
cinating. After college, I 
was again supposed to go 
back to Germany. I even 
had a one-way airplane 
ticket ready to go, but I 
called and cancelled it. That 
felt, even at the time, like 
one of those major life- 
altering decisions. If I hadn’t 
stayed, I would not have 
been in the same environ-
ment or met the people who 
helped me get to where I am today. But I 
did stay, and I worked for a year as a tech-
nician with a small biotech fi  rm in the Bay 
Area. I hadn’t really decided what I wanted 
to do next, but while I was at that company, 
I heard about the pharmaceutical chemistry 
program at UCSF. I decided to enroll as a 
graduate student there.
SERENDIPITY
What made you decide to pursue a 
graduate degree?
In the end what really interests me is the 
idea of applying chemistry and biology 
to questions related to human disease. I 
didn’t recognize that at the time, but 
looking back, I see that most of the deci-
sions I’ve made were guided by that. In 
fact, I’m currently helping to set up a 
new cancer center here in Dundee, so 
I’m able to pursue that interest more di-
rectly. But at the time, I just felt that 
there were many interesting questions 
out there that I could work on. I wasn’t 
driven by any particular problem.
I did my graduate work with Frances 
Brodsky, where I worked on clathrin 
structure and function. That work—and 
just being at UCSF, where cell biology 
was really coming into its own—intro-
duced me to a lot of cell biology–related 
questions. When the time came to decide 
on a postdoctoral position, I spoke to a 
number of different people, and in the end 
I joined James Nelson’s lab at Stanford to 
work on cell adhesion.
Näthke investigates the many functions of adenomatous polyposis coli 
protein and its contribution to human disease.
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It was during your postdoc that you ﬁ  rst 
encountered APC?
That was serendipity—I just happened to 
be in the right place at the right time. I had 
been working with a graduate student in 
James’ lab on the interaction between cat-
enins and cadherins. We’d made some anti-
bodies to catenins, in particular -catenin, 
because catenins had just been discovered 
and there weren’t many good antibodies 
around at the time. One day, Paul Polakis 
called James looking for antibodies to 
-catenin, and we sent him some of ours. 
In return, Paul gave us some of his anti-
bodies to this protein he’d been working 
on, APC. APC is a monster of a protein, 
and Paul had done the early biochemical 
work on it. He had data suggesting APC 
might interact with microtubules, so I 
decided to see if his antibody worked for 
immunofl  uorescence. I remember looking 
in the microscope and seeing that APC 
was in these little clusters on micro-
tubules, and saying to myself, “What’s 
going on here? This is really different!” I 
decided I wanted to know more about this 
protein and its role in cells.
OPPORTUNITY
What about APC captivated you?
Initially I was just intrigued by the really 
striking localization pattern that it exhib-
ited. But the more I worked on it, the more 
interested I became. Of course, APC is 
famous for helping to regulate -catenin as 
part of the Wnt signaling pathway, and 
for the connection that has to cancer. But 
that’s not all there is to APC. It’s an adap-
tor protein, so it has its fi  ngers in a lot of 
different pies in the cell, but it turns out 
that it isn’t absolutely needed for any-
thing it does. You can knock it out and 
nothing dramatic happens. Cells that lack 
APC still move and grow, and although 
they don’t differentiate as well, they can 
still divide. The fi  delity of mitosis is de-
fective, so cells make more 
mistakes. But these mis-
takes are tolerated, and the 
cell can keep growing and 
proliferating. But without 
APC, all these processes 
are slightly off-kilter; all 
these little errors push the 
cell just that much closer to 
having a real problem—to 
becoming cancerous. All you need is one 
more nudge in that direction for the real 
trouble to start.
We think this is why you see APC 
mutations so frequently in colon cancer. 
The intestine is not a friendly environ-
ment; gut epithelial cells only last about 
fi  ve days so they must be continually 
replaced. As a result, gut tissue is uniquely 
dependent on adhesion, migration, pro-
liferation, differentiation, and apoptosis—
and APC touches on all these processes. 
APC mutations might permit cells to 
persist for a longer time in the toxic gut 
environment and to tolerate small errors, 
so they have a greater opportunity to 
accumulate additional genetic hits and 
become cancerous.
Where are your research interests 
taking you now?
There are obviously lots of angles 
from which we could approach 
working with APC, and that’s what 
I’ve built my career on. When I fi  rst 
established my lab here at Dundee, 
we worked on the hardcore cell bi-
ology of the protein, looking at its 
interactions with the cytoskeleton. 
But over the last several years, we 
and others have accumulated evi-
dence of new areas where APC 
plays a role—recently it’s even cropped 
up in DNA repair and in hypoxia. We’re 
now picking apart whether these are di-
rect or indirect links. We’re trying lots of 
new biochemical assays to look at APC’s 
interactions with other proteins, and using 
fl  uorescent probes to explore these inter-
actions in cells.
One of our goals is to explore how 
APC’s interactions with its partners are 
regulated. An increasingly important as-
pect of our work is to look 
at whole tissue physiology 
and whole tissue architec-
ture to see whether the 
changes we see in cells in 
Petri dishes translate into 
changes in gut tissue. We 
are even starting to explore, 
using a computer modeling 
approach, how mutations 
in APC affect the mechanical properties 
of gut tissue. It feels like a lot of work 
and my lab is pretty small, but I have a 
really talented and dedicated group of 
people who help shape each step in the 
work we’re doing. I love going to work 
in the morning.
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The elaborate architecture of gut tissue.
“APC has 
its fingers 
in a lot of 
different pies 
in the cell.”
Seeing APC (green) on microtubule (red) ends 
sparked Näthke’s curiosity.